Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

ADVERTISEMENT

Biosimilars Topic Center

Advertisement

Featured

Stephen Speicher, MD
Videos
Technology for Biosimilar Substitution to Enhance Practice Efficiency and Financial Health
03/01/2024

Featuring Stephen V. Speicher, MD, MS

Featuring Stephen V. Speicher, MD, MS...
Stephen V. Speicher, MD, MS, discusses his upcoming AMCCBS poster presentation titled “Technology for Substituting Biosimilars to Improve Practice Efficiency and Financial Health.”
Stephen V. Speicher, MD, MS, discusses his upcoming AMCCBS poster presentation titled “Technology for Substituting Biosimilars to Improve Practice Efficiency and Financial Health.”
Stephen V. Speicher, MD, MS,...
03/01/2024
Journal of Clinical Pathways
Andre Harvin, PharmD, MS, MBA
Videos
The Impact of Biosimilars on the Business of Oncology
03/28/2023
Andre Harvin, PharmD, MS, MBA, discusses controlling costs in the business of oncology through biosimilar use.
Andre Harvin, PharmD, MS, MBA, discusses controlling costs in the business of oncology through biosimilar use.
Andre Harvin, PharmD, MS, MBA,...
03/28/2023
Journal of Clinical Pathways
James Gelfand, JD
Videos
Analyzing Pharmacy Benefits in Value-Based Oncology Pathways
10/14/2022
James Gelfand, JD, The ERISA Industry Committee, discusses achieving optimal, value-driven patient care through pharmacy benefit managers, and changes in plan transparency for payers and patients at the 2022 Oncology Clinical Pathways...
James Gelfand, JD, The ERISA Industry Committee, discusses achieving optimal, value-driven patient care through pharmacy benefit managers, and changes in plan transparency for payers and patients at the 2022 Oncology Clinical Pathways...
James Gelfand, JD, The ERISA...
10/14/2022
Journal of Clinical Pathways
Conference Coverage
Therapeutic Interchange Reduces Cost While Maintaining Quality of Care in the US Oncology Care Model
10/01/2022

Katie Herman

Katie Herman
At the 2022 ASCO Quality Care Symposium, Ives and colleagues concluded that therapeutic interchange is an effective way to reduce total cost of care while maintaining the quality of care in the Oncology Care Model.
At the 2022 ASCO Quality Care Symposium, Ives and colleagues concluded that therapeutic interchange is an effective way to reduce total cost of care while maintaining the quality of care in the Oncology Care Model.
At the 2022 ASCO Quality Care...
10/01/2022
Journal of Clinical Pathways
Research Reports
Improving Biosimilar Adoption Rates and Affordability With Oncology Pathways
08/15/2022
Stephen Hamilton, MD
Kathryn Christensen, MS
Margaret Rausa, PharmD
Nick Andrews, PharmD
Timothy Dollear, MS
Christopher Linkimer, CPA
Eric Gratias, MD, FAAP
Dr Hamilton and colleagues outline how eviCore Healthcare offered the option for payer clients to implement a biosimilar preferencing policy, analyzing how this policy affected the rate of biosimilar use and costs.
Dr Hamilton and colleagues outline how eviCore Healthcare offered the option for payer clients to implement a biosimilar preferencing policy, analyzing how this policy affected the rate of biosimilar use and costs.
Dr Hamilton and colleagues...
08/15/2022
Journal of Clinical Pathways
Puneeth Indurlal, MD, MS
Videos
Analyzing the Financial Impact of Biosimilar Use in the Oncology Care Model for the US Oncology Network
07/12/2022
Puneeth Indurlal, MD, MS, describes his study on the utilization and financial impact of abiraterone therapeutic interchange in The Network during an Oncology Care Model performance period, a value-based care program from Medicare that...
Puneeth Indurlal, MD, MS, describes his study on the utilization and financial impact of abiraterone therapeutic interchange in The Network during an Oncology Care Model performance period, a value-based care program from Medicare that...
Puneeth Indurlal, MD, MS,...
07/12/2022
Journal of Clinical Pathways
Conference Coverage
Standardizing Utilization of Biosimilars in Oncology
07/06/2022

Ellen Kurek

Ellen Kurek
Findings from a recent real-world study suggest that use of an integrated electronic health record to standardize biosimilar utilization in oncology may reduce costs, without compromising quality and safety in care. 
Findings from a recent real-world study suggest that use of an integrated electronic health record to standardize biosimilar utilization in oncology may reduce costs, without compromising quality and safety in care. 
Findings from a recent...
07/06/2022
Journal of Clinical Pathways
Conference Coverage
Impact of Biosimilar Substitution on Provider Risk in Value-Based Oncology Payment Models
06/14/2022

Ellen Kurek

Ellen Kurek
Researchers at the 2022 ASCO Annual Meeting estimated the impact of biosimilar substitution on financial risk to providers in oncology value-based payments by applying simulation approaches to model the episode framing, pricing, and risk...
Researchers at the 2022 ASCO Annual Meeting estimated the impact of biosimilar substitution on financial risk to providers in oncology value-based payments by applying simulation approaches to model the episode framing, pricing, and risk...
Researchers at the 2022 ASCO...
06/14/2022
Journal of Clinical Pathways
News
Cost-Effectiveness of Primary Prophylaxis With G-CSF Biosimilars in Patients at Risk of Febrile Neutropenia
06/12/2022

Ellen Kurek

Ellen Kurek
PEG biosimilars may be able to optimize febrile neutropenia management among patients with intermediate-to-high risk febrile neutropenia while minimizing costs.
PEG biosimilars may be able to optimize febrile neutropenia management among patients with intermediate-to-high risk febrile neutropenia while minimizing costs.
PEG biosimilars may be able to...
06/12/2022
Journal of Clinical Pathways
News
Trastuzumab Biosimilar Plus Pertuzumab for HER2-Positive Metastatic Breast Cancer Treated With Chemotherapy
06/09/2022

Ellen Kurek

Ellen Kurek
A research group in Denmark determined that median progression-free-survival with SB3 was comparable with that of reference trastuzumab for patients with HER2-positive metastatic breast cancer treated with chemotherapy.
A research group in Denmark determined that median progression-free-survival with SB3 was comparable with that of reference trastuzumab for patients with HER2-positive metastatic breast cancer treated with chemotherapy.
A research group in Denmark...
06/09/2022
Journal of Clinical Pathways
News
Bevacizumab-bvzr Biosimilar Used Most Frequently for Metastatic Colorectal Cancer in US Oncology Practice, According to Retrospective Cohort Study
06/09/2022

Ellen Kurek

Ellen Kurek
This study finds that US oncologists have adopted switching between the bevacizumab reference product and bevacizumab biosimilars as well as using bevacizumab-bvzr in chemotherapy combination regimens.
This study finds that US oncologists have adopted switching between the bevacizumab reference product and bevacizumab biosimilars as well as using bevacizumab-bvzr in chemotherapy combination regimens.
This study finds that US...
06/09/2022
Journal of Clinical Pathways

Advertisement

Expert Insights

Gary Lyman, MD
Interview
Do Oncology Biosimilars Have a Place in Clinical Pathways?
08/30/2018
Gary Lyman, MD, MPH, explains the process of bringing oncology biosimilars to market and their potential uptake in clinical practice as well as pathways.
Gary Lyman, MD, MPH, explains the process of bringing oncology biosimilars to market and their potential uptake in clinical practice as well as pathways.
Gary Lyman, MD, MPH, explains...
08/30/2018
Journal of Clinical Pathways
Gunjan Sharma
Interview
Leveraging Data to Enhance Patient Care: Addressing Social Determinants of Health in Oncology Care
07/10/2024
US Oncology Network analyst Gunjan Sharma shares insights on the impact of health-related social needs, Beer’s criteria medication prescribing patterns, and how research can inform the development of support services for patients with cancer.
US Oncology Network analyst Gunjan Sharma shares insights on the impact of health-related social needs, Beer’s criteria medication prescribing patterns, and how research can inform the development of support services for patients with cancer.
US Oncology Network analyst...
07/10/2024
Journal of Clinical Pathways
Stephen Colvill, MBA
Conference Coverage
How Collaboration Among Health Care Stakeholders Can Help Mitigate Drug Shortages
07/08/2024
Stephen Colvill, MBA, discusses how collaboration, proactive strategies, and technology can help prevent drug shortages.
Stephen Colvill, MBA, discusses how collaboration, proactive strategies, and technology can help prevent drug shortages.
Stephen Colvill, MBA, discusses...
07/08/2024
Journal of Clinical Pathways
Paul Fu, MD
Interview
How Technology Can Improve Health Care Team Communication
06/17/2024
Paul Fu Jr, MD, MPH, City of Hope National Medical Center
Paul Fu Jr, MD, MPH, discusses the benefits of using technology to assist health team communication practices.
Paul Fu Jr, MD, MPH, discusses the benefits of using technology to assist health team communication practices.
Paul Fu Jr, MD, MPH, discusses...
06/17/2024
Journal of Clinical Pathways
Interview
Oncology Drug Shortages: Causes and Solutions
05/28/2024

 Ryan Motte, PharmD, CSP, Shields Health Solutions

 Ryan Motte, PharmD, CSP, Shields Hea...
Ryan Motte, PharmD, discusses how oncology drug shortages have impacted patients with chronic lymphocytic leukemia.
Ryan Motte, PharmD, discusses how oncology drug shortages have impacted patients with chronic lymphocytic leukemia.
Ryan Motte, PharmD, discusses...
05/28/2024
Journal of Clinical Pathways
Shaalan Beg, MD
Interview
CLL Treatment Updates and the Integration of AI into CLL Clinical Trials
05/20/2024
Shaalan Beg, MD, MBA, FASCO
Shaalan Beg, MD, MBA, FASCO, describes some of the recent advancements in the treatment of chronic lymphocytic leukemia (CLL).
Shaalan Beg, MD, MBA, FASCO, describes some of the recent advancements in the treatment of chronic lymphocytic leukemia (CLL).
Shaalan Beg, MD, MBA, FASCO,...
05/20/2024
Journal of Clinical Pathways
Kerry Rogers, MD
Interview
Venetoclax Plus Ibrutinib Combination Therapy for Treating Patients With CLL With Resistance Mutations
04/19/2024

Featuring Kerry Rogers, MD, The Ohio State University

Featuring Kerry Rogers, MD, The Ohio ...
Kerry Rogers, MD, The Ohio State University, discusses results from her study on how Bruton tyrosine kinase (BTK) inhibitors ibrutinib and venetoclax could help eliminate molecular resistance in patients with CLL who have resistance mutations.
Kerry Rogers, MD, The Ohio State University, discusses results from her study on how Bruton tyrosine kinase (BTK) inhibitors ibrutinib and venetoclax could help eliminate molecular resistance in patients with CLL who have resistance mutations.
Kerry Rogers, MD, The Ohio State...
04/19/2024
Journal of Clinical Pathways
Interview
Chronic Lymphocytic Leukemia Pathways in Practice at Rocky Mountain Cancer Centers
03/27/2024
John Burke, MD, discusses the current treatment landscape for chronic lymphocytic leukemia and describes how his center ensures a comprehensive approach to patient care.
John Burke, MD, discusses the current treatment landscape for chronic lymphocytic leukemia and describes how his center ensures a comprehensive approach to patient care.
John Burke, MD, discusses the...
03/27/2024
Journal of Clinical Pathways
Bradley Corr, MD
Conference Coverage
Rucaparib Maintenance Therapy Improved Progression-Free Survival Among Patients With Recurrent or Metastatic Endometrial Cancer
03/21/2024

Featuring Bradley Corr, MD

Featuring Bradley Corr, MD
At the 2024 SGO Annual Meeting on Women’s Cancers, Bradley Corr, MD, discusses the results from a study evaluating rucaparib maintenance therapy for patients with metastatic or recurrent endometrial cancer.
At the 2024 SGO Annual Meeting on Women’s Cancers, Bradley Corr, MD, discusses the results from a study evaluating rucaparib maintenance therapy for patients with metastatic or recurrent endometrial cancer.
At the 2024 SGO Annual Meeting...
03/21/2024
Oncology
Jing-Zhou Hou, MD, PhD
Videos
Clinical and Demographic Factors Impacting Treatment Selection for Patients With CLL in Community Oncology Settings
03/21/2024

Featuring Jing-Zhou Hou, MD, PhD

Featuring Jing-Zhou Hou, MD, PhD ...
Jing-Zhou Hou, MD, PhD, discusses how the standard of care for CLL has evolved among community oncologists since 2020 and how clinical and demographic factors impact treatment selection.
Jing-Zhou Hou, MD, PhD, discusses how the standard of care for CLL has evolved among community oncologists since 2020 and how clinical and demographic factors impact treatment selection.
Jing-Zhou Hou, MD, PhD,...
03/21/2024
Journal of Clinical Pathways
Michiel van der Heijden, MD 
Conference Coverage
Enfortumab Vedotin Plus Pembrolizumab Potential New Standard of Care for Advanced Urothelial Carcinoma in the First-Line Setting
01/26/2024

Featuring Michiel van der Heijden, MD 

Featuring Michiel van der Heijden, MD...
Michiel van der Heijden, MD, discusses the subgroup analyses of the phase 3 EV-302 study, evaluating enfortumab vedotin plus pembrolizumab among patients with locally advanced or metastatic urothelial carcinoma in the first-line setting.
Michiel van der Heijden, MD, discusses the subgroup analyses of the phase 3 EV-302 study, evaluating enfortumab vedotin plus pembrolizumab among patients with locally advanced or metastatic urothelial carcinoma in the first-line setting.
Michiel van der Heijden, MD,...
01/26/2024
Oncology

Newsfeed

News
Cost-Effectiveness of Primary Prophylaxis With G-CSF Biosimilars in Patients at Risk of Febrile Neutropenia
06/12/2022

Ellen Kurek

Ellen Kurek
PEG biosimilars may be able to optimize febrile neutropenia management among patients with intermediate-to-high risk febrile neutropenia while minimizing costs.
PEG biosimilars may be able to optimize febrile neutropenia management among patients with intermediate-to-high risk febrile neutropenia while minimizing costs.
PEG biosimilars may be able to...
06/12/2022
Journal of Clinical Pathways
News
Trastuzumab Biosimilar Plus Pertuzumab for HER2-Positive Metastatic Breast Cancer Treated With Chemotherapy
06/09/2022

Ellen Kurek

Ellen Kurek
A research group in Denmark determined that median progression-free-survival with SB3 was comparable with that of reference trastuzumab for patients with HER2-positive metastatic breast cancer treated with chemotherapy.
A research group in Denmark determined that median progression-free-survival with SB3 was comparable with that of reference trastuzumab for patients with HER2-positive metastatic breast cancer treated with chemotherapy.
A research group in Denmark...
06/09/2022
Journal of Clinical Pathways
News
Bevacizumab-bvzr Biosimilar Used Most Frequently for Metastatic Colorectal Cancer in US Oncology Practice, According to Retrospective Cohort Study
06/09/2022

Ellen Kurek

Ellen Kurek
This study finds that US oncologists have adopted switching between the bevacizumab reference product and bevacizumab biosimilars as well as using bevacizumab-bvzr in chemotherapy combination regimens.
This study finds that US oncologists have adopted switching between the bevacizumab reference product and bevacizumab biosimilars as well as using bevacizumab-bvzr in chemotherapy combination regimens.
This study finds that US...
06/09/2022
Journal of Clinical Pathways
News
Outcomes of Treatment With Cancer Biosimilars Found Equal to Those of the Reference Drug in Harvard Systematic Review and Meta-Analysis
05/11/2022

Ellen Kurek

Ellen Kurek
Study findings show that results of rigorous clinical evaluation of cancer drug biosimilars were statistically indistinguishable when compared with the results of evaluations of the reference drug across subgroups of drugs, cancer types, and...
Study findings show that results of rigorous clinical evaluation of cancer drug biosimilars were statistically indistinguishable when compared with the results of evaluations of the reference drug across subgroups of drugs, cancer types, and...
Study findings show that results...
05/11/2022
Journal of Clinical Pathways
News
Biosimilar vs Referent Trastuzumab for the Neoadjuvant Treatment of ERBB2–Positive Breast Cancer
04/14/2022

Ellen Kurek

Ellen Kurek
Biosimilar HD201 demonstrates equal efficacy to referent trastuzumab in total pathological complete response and safety in ERBB2–positive breast cancer, according to results from the TROIKA trial.
Biosimilar HD201 demonstrates equal efficacy to referent trastuzumab in total pathological complete response and safety in ERBB2–positive breast cancer, according to results from the TROIKA trial.
Biosimilar HD201 demonstrates...
04/14/2022
Journal of Clinical Pathways
News
Trastuzumab Biosimilars Safe, Effective Among Patients With HER2-Positive Breast Cancer
03/07/2022

Marta Rybczynski

Marta Rybczynski
Study findings show that trastuzumab biosimilars are safe and effective compared to the reference drug and improve patients' accessibility to breast cancer treatment.
Study findings show that trastuzumab biosimilars are safe and effective compared to the reference drug and improve patients' accessibility to breast cancer treatment.
Study findings show that...
03/07/2022
Journal of Clinical Pathways
News
Biosimilars Provide Lower-Cost Alternatives to Biologics Used in Cancer Care
02/25/2022
Findings from a recent update on currently approved oncology biosimilars suggests that the use of biosimilars might provide competitive, lower-cost alternatives to biologics used in oncology.
Findings from a recent update on currently approved oncology biosimilars suggests that the use of biosimilars might provide competitive, lower-cost alternatives to biologics used in oncology.
Findings from a recent update on...
02/25/2022
Journal of Clinical Pathways
News
Cost-Effectiveness of Primary Prophylaxis With Biosimilar Filgrastim for Patients at Risk for Febrile Neutropenia
02/21/2022

Janelle Bradley

Janelle Bradley
Study findings reveal primary prophylaxis with biosimilar filgrastim-sndz is cost-effective in patients with cancer at intermediate risk for febrile neutropenia.
Study findings reveal primary prophylaxis with biosimilar filgrastim-sndz is cost-effective in patients with cancer at intermediate risk for febrile neutropenia.
Study findings reveal primary...
02/21/2022
Journal of Clinical Pathways
News
Conversion to Biosimilar Neutropenia Prophylaxis Generates Cost-Savings and Provides Access to Pancreatic Cancer Treatment
02/11/2022

Janelle Bradley

Janelle Bradley
Conversion to biosimilar pegfilgrastim-cbqv for neutropenia prophylaxis can generate potential cost-savings and provide budget-neutral expanded access to FOLFIRINOX treatment for patients with metastatic pancreatic cancer.
Conversion to biosimilar pegfilgrastim-cbqv for neutropenia prophylaxis can generate potential cost-savings and provide budget-neutral expanded access to FOLFIRINOX treatment for patients with metastatic pancreatic cancer.
Conversion to biosimilar...
02/11/2022
Journal of Clinical Pathways
News
Biosimilar Trastuzumab is Cost-Efficient Over Reference Trastuzumab for Metastatic Breast Cancer
02/10/2022

Janelle Bradley

Janelle Bradley
Study findings suggest biosimilar intravenous trastuzumab-dkst is cost-efficient over reference intravenous and subcutaneous trastuzumab in metastatic breast cancer.
Study findings suggest biosimilar intravenous trastuzumab-dkst is cost-efficient over reference intravenous and subcutaneous trastuzumab in metastatic breast cancer.
Study findings suggest...
02/10/2022
Journal of Clinical Pathways
News
Examining Treatment Delay Trends in Patients With Lung Cancer
07/24/2024
A study in Missouri uncovers a disturbing trend of increasing delays in lung cancer treatment initiation, surpassing national guidelines and prompting a call for further investigation into potential causes.
A study in Missouri uncovers a disturbing trend of increasing delays in lung cancer treatment initiation, surpassing national guidelines and prompting a call for further investigation into potential causes.
A study in Missouri uncovers a...
07/24/2024
Journal of Clinical Pathways
News
First-Line Amivantamab Plus Lazertinib Superior to Osimertinib Among Patients With Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
07/18/2024
Results from the phase 3 MARIPOSA study found that first-line amivantamab plus lazertinib demonstrated superior efficacy compared to osimertinib among patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.
Results from the phase 3 MARIPOSA study found that first-line amivantamab plus lazertinib demonstrated superior efficacy compared to osimertinib among patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.
Results from the phase 3...
07/18/2024
Oncology
News
Perioperative Nivolumab Prolonged Event-Free Survival Compared to Perioperative Chemotherapy Among Patients With Resectable Non-Small Cell Lung Cancer
07/15/2024
Results from the phase 3 CheckMate 77T trial demonstrated that perioperative nivolumab prolonged event-free survival compared to perioperative chemotherapy among patients with resectable non-small cell lung cancer.
Results from the phase 3 CheckMate 77T trial demonstrated that perioperative nivolumab prolonged event-free survival compared to perioperative chemotherapy among patients with resectable non-small cell lung cancer.
Results from the phase 3...
07/15/2024
Oncology
News
Improving Care for Patients With Cancer Through Early Goal of Care Discussions
07/03/2024
Standardizing electronic documentation of physician-led goals of care discussions in patients with cancer can lead to improved care integration across health care settings, ensuring comprehensive and individualized quality care for patients...
Standardizing electronic documentation of physician-led goals of care discussions in patients with cancer can lead to improved care integration across health care settings, ensuring comprehensive and individualized quality care for patients...
Standardizing electronic...
07/03/2024
Journal of Clinical Pathways
Conference Coverage
The Association Between High Deductible Health Plans and Cancer Survival
07/02/2024
According to findings presented at ASCO 2024, researchers found that high deductible health plans are associated with worse survival in cancer survivors.
According to findings presented at ASCO 2024, researchers found that high deductible health plans are associated with worse survival in cancer survivors.
According to findings presented...
07/02/2024
Journal of Clinical Pathways
News
Impact of Care Delays on Health Care Resource Utilization in Patients With Early-Stage Lung Cancer
06/26/2024

Brandon Twyford

Brandon Twyford
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on...
06/26/2024
Journal of Clinical Pathways
News
GE HealthCare Introduces New Precision Care Tools to Expand Access to Personalized Medicine
06/10/2024
Grace Taylor, MS, MA
General Electric (GE) HealthCare premiered its new precision care tools to expand the practice of more personalized medicine internationally.
General Electric (GE) HealthCare premiered its new precision care tools to expand the practice of more personalized medicine internationally.
General Electric (GE) HealthCare...
06/10/2024
Journal of Clinical Pathways
News
Phase 3 KEYNOTE-522 Trial Meets Overall Survival Endpoints in Patients With TNBC
05/30/2024
Grace Taylor, MS, MA
Merck announced that their phase 3 KEYNOTE-522 trial evaluating pembrolizumab (Keytruda) met its overall survival endpoint for treating patients with high-risk early-state triple-negative breast cancer (TNBC).
Merck announced that their phase 3 KEYNOTE-522 trial evaluating pembrolizumab (Keytruda) met its overall survival endpoint for treating patients with high-risk early-state triple-negative breast cancer (TNBC).
Merck announced that their phase...
05/30/2024
Journal of Clinical Pathways
News
Ajax Therapeutics Receives FDA Clearance to Initiate Phase 1 Clinical Study of AJ1-11095 for Myelofibrosis
05/23/2024
Grace Taylor, MS, MA
Ajax Therapeutics received clearance from the US Food and Drug Administration (FDA) to begin a phase 1 clinical study of AJ1-11095, a first-in-class type 2 JAK2 inhibitor, for treating myelofibrosis.
Ajax Therapeutics received clearance from the US Food and Drug Administration (FDA) to begin a phase 1 clinical study of AJ1-11095, a first-in-class type 2 JAK2 inhibitor, for treating myelofibrosis.
Ajax Therapeutics received...
05/23/2024
Journal of Clinical Pathways
News
Patients With Breast Cancer Experience High Economic Burden and Lower HRQoL: Literature Review
05/15/2024
Grace Taylor, MS, MA
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review...
05/15/2024
Journal of Clinical Pathways

From the Journal

Research Reports
Improving Biosimilar Adoption Rates and Affordability With Oncology Pathways
08/15/2022
Stephen Hamilton, MD
Kathryn Christensen, MS
Margaret Rausa, PharmD
Nick Andrews, PharmD
Timothy Dollear, MS
Christopher Linkimer, CPA
Eric Gratias, MD, FAAP
Dr Hamilton and colleagues outline how eviCore Healthcare offered the option for payer clients to implement a biosimilar preferencing policy, analyzing how this policy affected the rate of biosimilar use and costs.
Dr Hamilton and colleagues outline how eviCore Healthcare offered the option for payer clients to implement a biosimilar preferencing policy, analyzing how this policy affected the rate of biosimilar use and costs.
Dr Hamilton and colleagues...
08/15/2022
Journal of Clinical Pathways
Research Reports
Implications of Manufacturer Contracting: A Quantitative Model to Assess Biosimilar Market Feasibility
10/15/2018
Michael Kuehn, RPh
Jay Galli
Abstract: Eight years have passed since Congress enacted the Biologics Price Competition and Innovation Act (BPCIA) of 2010. Since then, 12 biosimilars have received approval from the Food and Drug Administration,...
Abstract: Eight years have passed since Congress enacted the Biologics Price Competition and Innovation Act (BPCIA) of 2010. Since then, 12 biosimilars have received approval from the Food and Drug Administration,...
...
10/15/2018
Journal of Clinical Pathways
Research Reports
Community Oncologists` Perception and Acceptance of Biosimilars in Oncology
09/13/2018
Chadi Nabhan, MD, MBA, FACP
Yolaine Jeune-Smith, PhD
Amy Valley, PharmD
Bruce A Feinberg, DO
Abstract: Biosimilars are hypothesized to contribute to lowering health care costs by entering the market at a discounted price compared with their reference biologics. Until recently, only filgrastim biosimilars...
Abstract: Biosimilars are hypothesized to contribute to lowering health care costs by entering the market at a discounted price compared with their reference biologics. Until recently, only filgrastim biosimilars...
...
09/13/2018
Journal of Clinical Pathways
From the Field
Shifting the Paradigm: The Impact of AI at the Point of Care in Cancer Treatment
06/03/2024
Stephen Speicher, MD, MS
Will Shapiro
Taylor Dias-Foundas
This report explores the transformative impact of artificial intelligence (AI) in health care, emphasizing its potential paradigm shift and current deployment in oncology.
This report explores the transformative impact of artificial intelligence (AI) in health care, emphasizing its potential paradigm shift and current deployment in oncology.
This report explores the...
06/03/2024
Journal of Clinical Pathways
Research Reports
PSA Outcomes and Clinical Surveillance Among Patients With Nonmetastatic Castration-Resistant Prostate Cancer Treated With a Next-Generation Androgen Receptor Inhibitor in Urology Practices With or Without In-Office Dispensing
06/03/2024
Sabree C. Burbage, PharmD
Dexter Waters, MSPH
Carmine Rossi, PhD
Frederic Kinkead, MA
Erik Muser, PharmD
Lorie Ellis, PhD
Patrick Lefebvre, MA
Dominic Pilon, MA
This study describes prostate-specific antigen (PSA) outcomes and clinical surveillance patterns among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) receiving next-generation androgen receptor inhibitors (ARIs)...
This study describes prostate-specific antigen (PSA) outcomes and clinical surveillance patterns among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) receiving next-generation androgen receptor inhibitors (ARIs)...
This study describes...
06/03/2024
Journal of Clinical Pathways
From the Field
Bringing Value to Health Care
06/03/2024
Andrew Pecora, MD
Lili Brillstein, MPH
Maher Albitar, MD
Nasim Asfar, MD, MBA, SFHM
Joel Brill, MD
Jeffrey R. Curtis, MD, MS, MPH
Andrew von Eschenbach, MD
Deborah Goss, MD
Andre Goy, MD
Max Holfert
Andrew Ip, MD, MS
Allen Karp
Mark Lutes
Steven Madreperla, MD, PhD
Patrick A. Roth, MD
Miruna Sasu
Robert Shelley
Robin L. Smith, MD, MBA
Nina Tandon, PhD, MBA
Dan Varga, MD
Richard Winters, MD
This paper provides insights and perspective from each constituent involved in shaping health care payment and delivery throughout the US.
This paper provides insights and perspective from each constituent involved in shaping health care payment and delivery throughout the US.
This paper provides insights and...
06/03/2024
Journal of Clinical Pathways
Research Reports
Patient-Reported Outcomes in Hematopoietic Stem Cell Transplant Recipients: Design, Implementation, and Pilot Results
02/21/2024
Christi Ann Hayes, MD
Aricca D. Van Citters, MS
Wenyan Zhao, PhD
Kate L. Caldon
Charlotte M. Coughenour
Tor D. Tosteson, PhD
Anna N. A. Tosteson, PhD
Kenneth R. Meehan, MD
In a recent study, Christi Ann Hayes, MD, and colleagues aimed to define patient-reported outcome measures in patients receiving hematopoietic stem cell transplant.
In a recent study, Christi Ann Hayes, MD, and colleagues aimed to define patient-reported outcome measures in patients receiving hematopoietic stem cell transplant.
In a recent study, Christi Ann...
02/21/2024
Journal of Clinical Pathways
From the Field
Comprehensive Genomic Testing: Tissue Stewardship and Best Practices
02/12/2024
Rebecca A. Previs, MD, MS
Maureen E. Cooper, BS
Kyle C. Strickland, MD
Heidi Ko, DO
Michelle F. Green, PhD
Faezeh Koohestani, PhD
Stephanie Hastings, PhD
Zachary Wallen, PhD
Sarabjot Pabla, PhD
Jeffrey M. Conroy, BS
Mary Nesline, MS
Shengle Zhang, MD
Durga Prasad Dash, PhD
Brian Caveney, MD, JD, MPH
Marcia Eisenberg, PhD
Eric Severson, MD, PhD
Shakti H. Ramkissoon, MD, PhD
Rebecca A. Previs, MD, et al provide an overview of current genomic testing methodologies and offer guidelines on best practices for tissue stewardship and preanalytic practices for successful comprehensive genomic profiling.
Rebecca A. Previs, MD, et al provide an overview of current genomic testing methodologies and offer guidelines on best practices for tissue stewardship and preanalytic practices for successful comprehensive genomic profiling.
Rebecca A. Previs, MD, et al...
02/12/2024
Journal of Clinical Pathways
Perspectives
The Key Factors Driving Low Participation in the Enhancing Oncology Model
02/12/2024
Theresa Dreyer, MPH
Theresa Dreyer, MPH, investigates the challenges leading to a substantial decline in participation among academic oncology practices within the Enhancing Oncology Model.
Theresa Dreyer, MPH, investigates the challenges leading to a substantial decline in participation among academic oncology practices within the Enhancing Oncology Model.
Theresa Dreyer, MPH,...
02/12/2024
Journal of Clinical Pathways
Research Reports
Enhancing Multidisciplinary Team Processes in Lung Cancer Care: A Self-Assessment Toolkit and Best Practices
02/09/2024
Poka Cui
Peter Blanshard
María Teresa Campos-Partera
Adrien Moucquot
S. Hassan R. Naqvi
David Dellamonica
Heather Moses
Poka Cui and colleagues completed a literature review along with interviews involving lung cancer multidisciplinary teams from 24 medical centers across Europe and Canada. In this report, they also introduce a comprehensive self-assessment...
Poka Cui and colleagues completed a literature review along with interviews involving lung cancer multidisciplinary teams from 24 medical centers across Europe and Canada. In this report, they also introduce a comprehensive self-assessment...
Poka Cui and colleagues...
02/09/2024
Journal of Clinical Pathways
Research Reports
The Impact of Social Determinants of Health Beyond Race on Survival in Metastatic Prostate Cancer: A Systematic Literature Review
12/14/2023
Stephen J. Freedland, MD
Imtiaz A. Samjoo, MSc, PhD
Emily Rosta, MSc
Austin Lansing, MSc
Alexandra Hall, MPH
Manvir Rai, BSc
Alexander Niyazov, PharmD, MPH
Jonathan L. Nazari, PharmD
Bhakti Arondekar, PhD, MBA
A systematic literature review by Stephen J. Freedland, MD, and colleagues summarizes the current evidence relating to social determinants of health beyond race and survival in patients with metastatic prostate cancer.
A systematic literature review by Stephen J. Freedland, MD, and colleagues summarizes the current evidence relating to social determinants of health beyond race and survival in patients with metastatic prostate cancer.
A systematic literature review...
12/14/2023
Journal of Clinical Pathways
Research Reports
Clinical and Economic Impact of Implementing HealthPathways at a Musculoskeletal Radiology Department
12/13/2023
Simon R. Davies, MBBCh, MD
Kathleen Lyons, MBBCh
Kausik Mukherjee, MBBS
Ramakrishna Kishore, MBBS
Khurram Hashmi, MBBCh
Maria Dyban, LLM
Anna Kuczynska, MBBCh
Simon R. Davies, MBBCh, and colleagues investigate the impact of HealthPathways on management and primary care clinicians in a musculoskeletal radiology department.
Simon R. Davies, MBBCh, and colleagues investigate the impact of HealthPathways on management and primary care clinicians in a musculoskeletal radiology department.
Simon R. Davies, MBBCh, and...
12/13/2023
Journal of Clinical Pathways
OCPC: IN SESSION
Artificial Intelligence in Oncology: The Wins, The Challenges, and How We Can Deliver on Personalized Cancer Care
09/19/2023
Matthew Biancalana, PhD
Tushar Pandey, MBA
Mathew Biancalana, PhD, and Tushar Pandey, MBA, discuss how artificial intelligence can enhance the field of precision medicine and help unburden physicians from laborious and repetitive tasks in diagnostic analyses.
Mathew Biancalana, PhD, and Tushar Pandey, MBA, discuss how artificial intelligence can enhance the field of precision medicine and help unburden physicians from laborious and repetitive tasks in diagnostic analyses.
Mathew Biancalana, PhD, and...
09/19/2023
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
Special Report
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
01/14/2021
01/14/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Recent Stories

Stephen Speicher, MD
Videos
Technology for Biosimilar Substitution to Enhance Practice Efficiency and Financial Health
03/01/2024

Featuring Stephen V. Speicher, MD, MS

Featuring Stephen V. Speicher, MD, MS...
Stephen V. Speicher, MD, MS, discusses his upcoming AMCCBS poster presentation titled “Technology for Substituting Biosimilars to Improve Practice Efficiency and Financial Health.”
Stephen V. Speicher, MD, MS, discusses his upcoming AMCCBS poster presentation titled “Technology for Substituting Biosimilars to Improve Practice Efficiency and Financial Health.”
Stephen V. Speicher, MD, MS,...
03/01/2024
Journal of Clinical Pathways
Andre Harvin, PharmD, MS, MBA
Videos
The Impact of Biosimilars on the Business of Oncology
03/28/2023
Andre Harvin, PharmD, MS, MBA, discusses controlling costs in the business of oncology through biosimilar use.
Andre Harvin, PharmD, MS, MBA, discusses controlling costs in the business of oncology through biosimilar use.
Andre Harvin, PharmD, MS, MBA,...
03/28/2023
Journal of Clinical Pathways
James Gelfand, JD
Videos
Analyzing Pharmacy Benefits in Value-Based Oncology Pathways
10/14/2022
James Gelfand, JD, The ERISA Industry Committee, discusses achieving optimal, value-driven patient care through pharmacy benefit managers, and changes in plan transparency for payers and patients at the 2022 Oncology Clinical Pathways...
James Gelfand, JD, The ERISA Industry Committee, discusses achieving optimal, value-driven patient care through pharmacy benefit managers, and changes in plan transparency for payers and patients at the 2022 Oncology Clinical Pathways...
James Gelfand, JD, The ERISA...
10/14/2022
Journal of Clinical Pathways
Conference Coverage
Therapeutic Interchange Reduces Cost While Maintaining Quality of Care in the US Oncology Care Model
10/01/2022

Katie Herman

Katie Herman
At the 2022 ASCO Quality Care Symposium, Ives and colleagues concluded that therapeutic interchange is an effective way to reduce total cost of care while maintaining the quality of care in the Oncology Care Model.
At the 2022 ASCO Quality Care Symposium, Ives and colleagues concluded that therapeutic interchange is an effective way to reduce total cost of care while maintaining the quality of care in the Oncology Care Model.
At the 2022 ASCO Quality Care...
10/01/2022
Journal of Clinical Pathways
Research Reports
Improving Biosimilar Adoption Rates and Affordability With Oncology Pathways
08/15/2022
Stephen Hamilton, MD
Kathryn Christensen, MS
Margaret Rausa, PharmD
Nick Andrews, PharmD
Timothy Dollear, MS
Christopher Linkimer, CPA
Eric Gratias, MD, FAAP
Dr Hamilton and colleagues outline how eviCore Healthcare offered the option for payer clients to implement a biosimilar preferencing policy, analyzing how this policy affected the rate of biosimilar use and costs.
Dr Hamilton and colleagues outline how eviCore Healthcare offered the option for payer clients to implement a biosimilar preferencing policy, analyzing how this policy affected the rate of biosimilar use and costs.
Dr Hamilton and colleagues...
08/15/2022
Journal of Clinical Pathways

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement